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Increased body mass index (BMI) is claimed to be a complication among survivors of testicular cancer (TCSs), especially after
receiving cisplatin-based chemotherapy. This study compares changes in BMI (kgm
 2) in TCSs with those observed in age-matched
men from the population (controls). Associations between treatment, age and potential BMI changes were sought. In 1999, a survey
was performed at the NRH of 444 unilaterally orchiectomised TCSs treated from 1980 to 1990. BMI at survey was recorded in each
TCS. Information on principal treatment (surgery only: SURG; radiotherapy only: RAD; chemotherapy 7 surgery or radiotherapy:
CHEM7) and pretreatment BMI was retrieved from the medical records. The age-matched controls had BMI measurements from
population surveys from 1985 and 1996. The annual BMI increase was calculated based on the difference in the two BMI
measurements divided by observation time. TCSs displayed a lower pretreatment mean BMI than the controls, whereas no difference
was found post-treatment. However, the annual BMI increase in TCSs exceeded that of the controls (0.19 vs 0.15, P¼1.4 10
 7).
The SURG and CHEM7 groups showed the greatest annual BMI increase. The multiple regression analysis showed that young TC
patients who received chemotherapy displayed an excessive annual BMI increase. Oncologists and young TCSs should be aware of
the risk of excessive BMI increase, in particular, after the use of chemotherapy.
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The mortality rates because of cancer have decreased in general,
and the prevalence of patients with a previous diagnosis of cancer
is increasing in society. This means that in future more cured
cancer patients will contact their family doctors and specialists
because of health problems associated with their history of
malignancy. In the last few years, oncologists have thus focused
on possible health risks among survivors of cancer, related to the
malignancy itself or its treatment.
Testicular cancer (TC) is the most frequent malignancy in men
aged 20–40 years, with an incidence rate approaching 9 per
100000 in Norway (1995–1997, Norwegian Cancer Register,
personal communication). After the introduction of cisplatin to
the treatment of TC, about 90% of these patients are cured. The
prevalence of TC survivors (TCSs) is consequently increasing. For
many years oncologists have claimed that TCSs have a similar life
expectancy as the age-matched males from the general population.
Recent publications (Berger et al, 1996; Bokemeyer et al, 1996;
Talvensaari et al, 1996; Gietema et al, 1992, 2001; Petersen et al,
1999; Akre et al, 2000; Meinardi et al, 2000a,b) have, however,
described long-term health problems among TCSs. Metabolic and
vascular problems have thus been claimed to be associated with
the treatment of TC. In particular, patients treated with cisplatin-
based chemotherapy are known to have a higher cardiovascular
morbidity. It is, however, not clear if the cardiovascular problems
seen in TCSs are associated with chemotherapy itself or are a
consequence of the metabolic changes (Syndrome X) or are related
to both.
In the last decade, an excessive weight increase has been
observed in the general population (Tverdal, 2001) and has
become a major health problem, as this condition is a significant
risk factor for a large number of diseases. In adult individuals,
weight gain is reflected by an increase of body mass index (BMI),
which represents the principal parameter for WHO’s definition of
obesity and overweight. Not only do obese patients develop
somatic diseases such as Syndrome X, cardiovascular diseases,
typeII diabetes mellitus, certain types of cancer and osteoarthritis,
but they also suffer from mental distress to a high extent (WHO,
1997). It is therefore of great importance to avoid overweight in
general, and to identify those long-term cancer survivors who
display an increased risk of developing overweight. For oncologists
treating TC, it is therefore of great interest to identify those
parameters and in particular those therapeutic modalities that are
related to the risk of excessive post-treatment increase of BMI.
Our group has recently performed a long-term follow-up survey
on TCSs (Fossa ˚ and Dahl, 2002). The obtained data on pre- and
post-treatment BMI in TCSs enabled the analysis of the following
research questions:
(1)
Is there an abnormal BMI increase among long-term TCSs
compared to a control group of age-matched men from the
normal population?
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To what extent is a potential BMI increase related to treatment?
PATIENTS AND METHODS
Eligibility
From 1998 to 2000 surviving Norwegian TC patients, aged 18–75
years and treated between 1980 and 1994, were invited to
participate in a national multicentre follow-up survey, which
aimed to assess long-term sequelae after treatment of TC (Fossa ˚
and Dahl, 2002).
The present paper comprises a subgroup of patients treated for
unilateral TC from 1980 to 1990 (T-1) at the Department of
Medical Oncology and Radiotherapy at the Norwegian Radium
Hospital (NRH), Oslo. Of the invited patients, 81% participated in
this study. Patients with bilateral TC or extragonadal germ cell
malignancy were excluded, as were those with previous unilateral
orchiectomy because of a benign condition and patients who, after
their diagnosis of TC, had been treated for a second malignancy
(Tables 1 and 2).
Treatment principles
Since 1980, cisplatin-based chemotherapy, retroperitoneal lymph
node dissection (RPLND) and infradiaphragmatic radiotherapy
have represented the principal postorchiectomy treatment mod-
alities for TC patients at NRH. Patients with early stages of
seminoma were in the 1990s treated with infradiaphragmatic
radiotherapy, whereas those with advanced stages were treated
with chemotherapy, occasionally followed by consolidation radio-
therapy. Up to 1987, patients with early stages of nonseminoma
underwent primary RPLND, followed by adjuvant chemotherapy
in case of metastases. From 1987 onwards diagnostic RPLND was
omitted as a routine in nonmetastatic cases, and the surveillance
policy or adjuvant chemotherapy was introduced. Metastatic cases
with nonseminomatous disease received cisplatin-based chemo-
therapy, followed by resection of residual tumour manifestations
(mostly RPLND). Relapsing patients were treated with additional
available chemotherapy. Based on these treatment principles, the
TCSs were allocated to three groups: (1) surgery only (SURG); (2)
radiotherapy only (RAD) and (3) chemotherapy with or without
surgery or radiotherapy (CHEM7) (Table 2).
Examination at long-term follow-up survey (T-2)
At T-2 (‘post-treatment’) the TCSs went through a physical
examination including measurements of height in centimetres and
weight in kilogrammes. Figures of weight and height before
treatment (‘pretreatment’) were retrieved from the patients’
medical records together with the patient’s age at the time of
treatment (T-1) of TC. The following age classes were defined
based on pretreatment age (AGE-1): (1) o29 years; (2) 30–39
years; (3) 40–49 years; (4) 450 years.
Reference group
The reference group consisted of age-matched men from the
HUNT studies (controls). The HUNT studies are health surveys
performed in the general population in Nord-Trndelag, a county
in Mid-Norway. The HUNT studies are generally regarded as a
survey of ‘Mini-Norway’. The purpose of these surveys was to
investigate the average health status in the adult population (age 4
20 years) of Nord-Trndelag. The HUNT studies are composed of
two parts: the first part was conducted in 1984–1985 (HUNT I, T-
1) and the second part in 1995–1997 (HUNT II, T-2). The survey
methods and participation rates are published elsewhere (Midthjell
et al, 1990, 1999).
To be eligible as a control person, the man’s weight and
height should have been recorded at HUNT I and HUNT II. Also,
the control person had to be younger than 75 years at T-2.
Approximately 3000 control persons did not fulfil these criteria
and were therefore excluded. For the purpose of the present study,
four age classes were established for the participants in HUNT
based on their age at HUNT I (AGE-1: (1) o29 years; (2) 30–39
years; (3) 40–49 years; (4) 450 years; Table 1).
BMI
For each individual among controls and TCSs, BMI was calculated
as weight in kilogrammes divided by the square of height in metres
(kgm
 2) for TCSs and controls. Each TCS and each HUNT
participant thus had two recordings of BMI (pre- and post-
treatment in TCSs; at HUNT I and HUNT II for controls): BMI-1
and BMI-2, respectively. The values of BMI were categorised
according to the recommendations from WHO (1997) regarding
the classification of BMI in adults:
Underweight
BMIo18.5
Normal range
BMI 18.5–24.9
Overweight
(without further consideration to defined subgroups) BMI X25.0
Annual BMI change was calculated as the difference between the
two BMI measurements divided by observation time in years
((BMI-2   BMI-1)years
 1).
Table 2 Demographics on TCSs according to treatment allocation
SURG
(92)
RAD
(170)
CHEM7
(182)
P
Age at T-1 (years) 30793 8 710 3079 o0.00
Age at T-2 (years) 44795 2 710 44710 o0.00
Marital status; % married
at T-2
67 67 65 0.92
Education; high school or
university (%) at T-2
44 50 49 0.45
Observation time (years) 14731 4 731 4 73 0.55
Nonseminomas 91 2 150 –
Seminomas 1 168 32 –
Stage
I 87 162 56 –
II 5 7 65 –
III 1 10 –
IV 51 –
Table 1 Demographics on controls (HUNT I and II) and all TCSs
HUNT All TCSs P
Age at T-1 (years) 41712 33710 o0.000
Age at T-2 (years) 52712 47711 o0.000
Marital status; % married at T-2 52 67 o0.000
Education; high school or
university (%) at T-2
29 50 o0.000
Observation time (years) 11711 4 73 o0.000
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The statistical analysis was performed using the package of
SPSS 9.0. Descriptive data are presented as mean and standard
deviation (s.d.), as well as mean and confidence interval (CI). w
2
test was used to analyse categorical data. Analysis of variance
was used for continuous data and post hoc tests were performed
with Bonferroni corrections. Linear regression analysis was used to
evaluate the impact of independent variables on annual BMI
change. All P-values were two-tailed. To account for multiple
comparisons, a value less than 0.01 was considered as statistically
significant.
ETHICS
The study was approved by the institutional and regional ethical
committees.
RESULTS
TCSs/controls
A total of 444 TCSs and 19224 controls fulfilled the eligibility
criteria for the study (Tables 1 and 2). The RAD group almost
exclusively consisted of patients with seminomas (99%) except for
two patients. The SURG group included patients with nonsemi-
nomatous disease except for one patient. A total of 82% of the
patients from the CHEM7 group had a nonseminomatous
tumour.
The mean observation time among the TCSs exceeded that of the
controls by about 3 years (P¼1.4 10
 15). At the time of
diagnosis, the TCSs were on average 8 years younger than their
controls at HUNT I (P¼1.1 10
 21). Of the TCSs, 43% (201) were
o29 years at the time of the diagnosis in comparison with 19%
(3992) of men aged o29 years in HUNT I. Statistically significant
differences of marital status and education levels were found
between TCSs and controls.
BMI-1
For all TCSs the mean BMI-1 was significantly below that of all
controls (23.8 vs 25.1kgm
 2; P¼1.1 10
 15). For both TSCs and
controls, BMI-1 increased with age at T-1, and significant
differences of BMI-1 were found between each of the four age
classes considering TCSs and controls separately (Figure 1A).
When only comparing BMI values of the youngest age class of
TCSs, BMI-1 was significantly below that of the comparable class
of the control (P¼0.00029).
Patients from each of the three treatment groups had a
significantly lower BMI-1 than the controls (Po0.01; Figure 1B).
Patients from the RAD group had the highest mean BMI-1
(P¼0.0072) and the lowest mean BMI-1 value was observed in the
CHEM7 group (P¼5.3 10
 15).
BMI-2
Considering all TCSs together the mean BMI-2 value was below
that of the controls, but did not reach our level of statistical
significance set at 0.01 (26.4 vs 26.7kgm
 2; P¼0.043; Figure 2A).
BMI-2 increased with the person’s age at T-1, and significant
differences of BMI-2 were found between men from the youngest
and the oldest age classes, independent of allocation to patient or
control group.
Comparing BMI-2 between TCSs and controls, no significant
differences were detectable within any of the four age classes. Even
in the youngest age groups of TCSs, BMI-2 was similar to that
observed in the controls.
Neither were significant differences of BMI-2 observed between
each of the three treatment groups and the controls (P40.01;
Figure 2B).
Annual BMI change
In general, the mean annual BMI change was higher among the
TCSs than the controls (0.19 vs 0.15; P¼1.4 10
 7). Age at T-1
was associated with BMI increase: significant differences were
observed between the age classes (Po0.01), displaying a lower
annual BMI increase in the older men than in the younger men.
The highest annual BMI changes were found in the two youngest
age classes, without statistically significant differences between
controls and TCSs (Figure 3A).
Comparing the three treatment groups to the controls, the SURG
group and the CHEM7 group displayed the highest value of
annual BMI change (P¼0.00073 resp. P¼1.5 10
 9; Figure 3B).
At T-1, 30% of the TCSs and 47% of the controls were classified
as overweight (BMI425kgm
 2). At T-2, the comparable percen-
tages had increased to 63% (TCSs) and 71% of the controls (data
not shown).
Annual BMI change, AGE-1 and treatment
AGE-1 as continuous variable and group allocation (SURG vs RAD
vs CHEM7 vs controls) were entered as independent predictors
into the linear regression analysis with annual BMI change as
dependent variable, pooling together TCSs and controls. AGE-1
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Figure 1 (A) Comparison of BMI-1 according to age classes (TCSs and
controls: P¼1.0 10
 15; K–K 95% CI for mean); (B) BMI-1 according
to treatment groups (SURG, RAD and CHEM7) and Controls (Po0.01;
K–K 95% CI for mean).
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 23) and belonging to CHEM7 (P¼0.013) remained
independent predictors of annual BMI change. This model
explained only 8% (R
2) of the annual BMI change.
DISCUSSION
This study shows that TCSs, approximately 14 years after their
treatment, displays an abnormal BMI increase compared to the
normal population. A high BMI increase is significantly associated
with the young age of a TC patient at diagnosis, with chemotherapy
as an additional independent parameter. Furthermore, our study
confirms previous observations of comparatively low mean BMI in
TC patients, in particular prior to treatment, but also 45 years
after treatment.
BMI-1 in TCSs was significantly below the average BMI-1 in the
controls. Especially, the younger TC patients had a lower BMI-1
than the controls. This surprising observation was also indicated in
previous studies from Denmark and Norway (Davies et al, 1990;
Akre et al, 2000). Both studies showed relatively low BMI
recordings years before the patients’ diagnosis. The reasons for
these observations remain unclear. Clinical experience indicates
that a poor nutritional status can be excluded as an explanation to
TC patients’ comparably low BMI at the time of diagnosis. This is
supported by a detailed analysis of our BMI-1 and pretreatment
weight recordings: no significant differences were found between
the four stages of testicular cancer (P¼0.057 and 0.078, resp.).
Subclinical variations of the serum androgens associated both with
BMI values and the aetiology of TC may explain some of the
observed differences, in particular in young individuals. Relatively
high serum testosterone levels, especially during puberty, have
been suggested to contribute to the development of TC (Rajpert-De
Meyts et al, 1993). Moss et al (1986) as well as the United Kingdom
Testicular Cancer Study Group (1994) found an association
beween young age at puberty and the risk of developing TC,
especially nonseminomatous disease. Serum testosterone is
inversely associated with BMI (Vermeulen, 1996). Recent observa-
tions claim that men with high BMI have a decreased risk of
developing TC (Akre et al, 2000). On the other hand, another study
indicates a decreased risk of developing TC with a more
adrenogenic state, such as baldness (Petridou et al, 1997). The
shown difference in BMI-1 between TCSs and controls could be
explained by such hormonal variations.
Epidemiological studies have shown a steady increase of the
average BMI in the normal population for the last 20–30 years, and
in particular over the last 3–5 years (Jacobsen et al, 2001). In
general, our TCSs follow this pattern: their post-treatment BMI is
above their pre-treatment BMI. Post-treatment BMI values that
exceed those of the general population have been described as a
long-term problem specific for TCSs, in particular after cisplatin-
based chemotherapy (Gietema et al, 1992). We could not confirm
these observations comparing BMI-2 in all TCSs and controls. On
the contrary, BMI-2 values in TCSs were significantly below those
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Figure 2 (A) Comparison of BMI-2 according to age classes (TCSs and
controls: P¼0.043; K–K 95% CI for mean). (B) BMI-2 according to
treatment groups (SURG, RAD, CHEM7) and controls (P40.01; K–K
95% CI for mean).
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Figure 3 (A) Annual BMI increase according to age classes (TCSs and
controls: P¼1.4 10
 7; K–K 95% CI for mean). (B) Annual BMI
increase according to treatment groups (SURG, RAD, CHEM7) and
controls (Po0.01; K–K 95% CI for mean).
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may be that not all reports have included adequate control groups.
It is extremely difficult to establish an adequate control group
measuring BMI in age-matched men from the normal population
performed approximately at the same time as in TCSs. Even the
present study suffers from some shortcomings in that respect. At
T-2, the controls in our study were on average 8 years older than
TCSs (Table 1). Furthermore, BMI-2 values of the controls were
obtained in 1995–1997 after an observation time that was 3 years
shorter than that on average in TCSs. Increasing age is associated
with increasing BMI until at least the 5–6th decade of life
(Jacobsen et al, 2001), whereas shorter observation time is
associated with a lower BMI value. As the effect of these
parameters (age, observation period and year to BMI measure-
ments) points in opposite directions, we nevertheless consider our
control group as adequate for BMI-2 comparisons between TCSs
and controls. Significant differences were also found when
comparing marital status and education level between TCSs and
controls. A low BMI is associated with marital status as well as high
education (Tverdal, 2001). These two factors are over-represented
among the TCSs at T-2, which could to some extent explain the
lower mean BMI-2 value, although we consider this impact as
rather limited.
After their treatment, TCSs do increase their BMI to a higher
extent than the controls. In our study, low age was the most
important predictive factor for a high BMI increase. In general,
BMI tends to rise more during adolescence and early adulthood
than during later life (WHO, 1997). Some of the observed
differences between TCSs and controls may thus be because of
the above-mentioned 8-year age difference of our main cohorts.
On the other hand, any clinical or subclinical postorchidectomy
hormone changes, if of impact on BMI development, may
be more pronounced in the younger than in the older TC patient.
Androgen insuffiency is, for example, often associated with
overweight, and may after orchidectomy be of particular
importance in the youngest age classes of TCSs, when serum
testosterone levels usually are high. Patients younger than 30 years
are those who have the highest risk of cancer in situ in the
contralateral testicle or are those who develop a new TC (Hoff
Wandera ˚s et al, 1997). This indicates that these patients most
probably more often than the older ones have histopathological
and functional abnormalities in the contralateral testicle, including
inadequate Leydig cell function (Bokemeyer et al, 1996). Owing to
these conditions, these young patients more often than the older
ones may suffer from subclinical androgen insufficiency after
unilateral orchidectomy.
It has earlier been argued that cisplatin-based chemotherapy in
particular leads to an abnormal BMI increase in TCSs possibly
related to hormonal changes that in turn lead to post-treatment
weight gain (Gietema et al, 1992). During recent years, it has been
pointed out that cisplatin-based chemotherapy may lead to
subclinical Leydig cell function (Vejby Hansen et al, 1989). A
significant difference concerning body fat has been reported in TC
patients who received chemotherapy at an age below 30 years
compared to those treated by orchidectomy only (Gietema et al,
1992). Our data support these observations to some extent. In the
linear regression analysis comprising all men from the control
group and all TCSs, young age was associated with a high annual
BMI increase. In addition, chemotherapy remained an additional
independent factor predicting a high annual BMI increase. Young
age is thus a ‘risk factor’ for high annual BMI increase, which
furthermore increases with chemotherapy.
Another important difference between the Gietema et al (1992)
study and ours was that the average observation period in the
former study was only 3 years as compared to 14 years in our
study. Any hormonal or metabolic changes leading to post-
treatment BMI increase may be more pronounced shortly after
chemotherapy than later on in life (Gietema et al, 1992; Berger et al,
1996).
Except for post-treatment hormone changes, one can only
speculate about other reasons for the high BMI increase in TCSs,
based on observations in other cancer survivors. It is known that
women with breast cancer, receiving adjuvant chemotherapy,
might develop excessive weight gain (Goodwin et al, 1988;
Jernstro ¨m et al, 1999). Overeating and less physical activity owing
to mental distress have been discussed together with hormonal
changes. A more recent theory is that chemotherapy would induce
hyperphagia (Demark-Wahnefried et al, 1993). All these para-
meters may explain the observed BMI increase in TCSs (Gietema
et al, 1992), especially in the younger ones, who have highest levels
of anxiety and fatigue (Fossa ˚ et al, 2002). Adolescence and early
adulthood are known to be critical periods for the development of
obesity (WHO, 1997).
According to WHO (1997), abnormal BMI increase in a person
as such is a serious health problem, not only the final result of such
development: overweight and obesity. In particular, any weight
gain at an early age is known to be a major health risk and could
contribute to the development of Syndrome X.
In conclusion, although post-treatment BMI values in long-term
TCSs do not exceed that of the normal age-matched male
population, the annual BMI increase in TCSs tends to exceed that
of the control group. Patients treated below the age of 30 years and,
in particular, after the application of chemotherapy, are at a high
risk of abnormal BMI increase. Physicians treating TC should be
aware of this health risk and advise their patients accordingly to
avoid subsequent somatic and psychological disabilities related to
overweight and obesity.
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